The use of isatuximab with the RVd regimen in the induction phase may improve minimal residual disease negativity rates in patients with multiple myeloma, phase 3 results show.
Chris Ryan
Articles by Chris Ryan
The ability to prolong central nervous system progression-free survival in patients with hormone receptor–positive, HER2-positive breast cancer has been demonstrated in an early clinical trial.